DE60218683D1 - Pharmazeutische zusammensetzung für die nasale verabreichung von östradiol und norethisteron - Google Patents

Pharmazeutische zusammensetzung für die nasale verabreichung von östradiol und norethisteron

Info

Publication number
DE60218683D1
DE60218683D1 DE60218683T DE60218683T DE60218683D1 DE 60218683 D1 DE60218683 D1 DE 60218683D1 DE 60218683 T DE60218683 T DE 60218683T DE 60218683 T DE60218683 T DE 60218683T DE 60218683 D1 DE60218683 D1 DE 60218683D1
Authority
DE
Germany
Prior art keywords
östradiol
norethisterone
pharmaceutical composition
nasal administration
nasal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60218683T
Other languages
English (en)
Other versions
DE60218683T2 (de
Inventor
Gilles Fonknechten
Patrick Wuthrich
Yannis Tsouderos
Claire Varin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Servier SAS filed Critical Laboratoires Servier SAS
Application granted granted Critical
Publication of DE60218683D1 publication Critical patent/DE60218683D1/de
Publication of DE60218683T2 publication Critical patent/DE60218683T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
DE60218683T 2001-07-19 2002-07-18 Pharmazeutische zusammensetzung für die nasale verabreichung von östradiol und norethisteron Expired - Fee Related DE60218683T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0109654A FR2827516B1 (fr) 2001-07-19 2001-07-19 Composition pharmaceutique pour l'administration par voie nasale d'estradiol et de norethisterone
FR0109654 2001-07-19
PCT/FR2002/002561 WO2003015751A1 (fr) 2001-07-19 2002-07-18 Composition pharmaceutique pour l'administration par voie nasale d'estradiol et de norethisterone

Publications (2)

Publication Number Publication Date
DE60218683D1 true DE60218683D1 (de) 2007-04-19
DE60218683T2 DE60218683T2 (de) 2007-12-27

Family

ID=8865701

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60218683T Expired - Fee Related DE60218683T2 (de) 2001-07-19 2002-07-18 Pharmazeutische zusammensetzung für die nasale verabreichung von östradiol und norethisteron

Country Status (20)

Country Link
US (1) US7182960B2 (de)
EP (1) EP1406591B1 (de)
JP (1) JP2005511496A (de)
AR (1) AR034810A1 (de)
AT (1) ATE355823T1 (de)
AU (1) AU2002336141B2 (de)
CA (1) CA2454671A1 (de)
CY (1) CY1106666T1 (de)
DE (1) DE60218683T2 (de)
DK (1) DK1406591T3 (de)
ES (1) ES2283596T3 (de)
FR (1) FR2827516B1 (de)
HU (1) HUP0400440A2 (de)
NO (1) NO20040104L (de)
NZ (1) NZ530537A (de)
PL (1) PL372325A1 (de)
PT (1) PT1406591E (de)
SI (1) SI1406591T1 (de)
WO (1) WO2003015751A1 (de)
ZA (1) ZA200400248B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2857594B1 (fr) * 2003-07-17 2005-09-16 Servier Lab Composition pharmaceutique pour l'administration par voie nasale de piribedil

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8801670A (nl) * 1988-07-01 1990-02-01 Walter Adrianus Josephus Johan Farmaceutisch preparaat.
BE1006873A6 (nl) * 1993-03-26 1995-01-10 Merkus Franciscus W H M Toedieningsformulering voor nasale insuline toediening.
BE1007402A5 (nl) * 1993-03-26 1995-06-06 Adir Nasale farmaceutische preparaten met progestagene stof.
SE9301171D0 (sv) * 1993-04-07 1993-04-07 Ab Astra Pharmaceutical composition containing lipophilic drugs
JP3545403B2 (ja) * 1993-04-22 2004-07-21 スカイファルマ インコーポレイテッド 医薬化合物を被包しているシクロデキストリンリポソーム及びその使用法
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
FR2784584B1 (fr) * 1998-10-14 2002-09-20 Adir Procede de preparation d'une solution pour pulverisation nasale contenant une ou plusieurs hormones sexuelles et une cyclodextrine

Also Published As

Publication number Publication date
EP1406591A1 (de) 2004-04-14
AU2002336141B2 (en) 2007-07-19
DE60218683T2 (de) 2007-12-27
SI1406591T1 (sl) 2007-06-30
AU2002336141B8 (en) 2003-03-03
NZ530537A (en) 2005-04-29
US7182960B2 (en) 2007-02-27
JP2005511496A (ja) 2005-04-28
WO2003015751A1 (fr) 2003-02-27
FR2827516A1 (fr) 2003-01-24
AR034810A1 (es) 2004-03-17
DK1406591T3 (da) 2007-06-25
FR2827516B1 (fr) 2003-09-19
ATE355823T1 (de) 2007-03-15
CA2454671A1 (fr) 2003-02-27
ZA200400248B (en) 2005-03-30
CY1106666T1 (el) 2012-05-23
EP1406591B1 (de) 2007-03-07
PT1406591E (pt) 2007-05-31
NO20040104L (no) 2004-01-19
US20040180856A1 (en) 2004-09-16
PL372325A1 (en) 2005-07-11
HUP0400440A2 (en) 2007-07-30
ES2283596T3 (es) 2007-11-01

Similar Documents

Publication Publication Date Title
DE60115418D1 (de) Mikroinfusionsvorrichtung zur verabreichung von medikamenten
DE50212302D1 (de) 17alpha-alkyl-17beta-oxy-estratriene und zwischenprodukte zu deren herstellung, verwendung der 17alpha-alkyl-17beta-oxy-estratriene zur herstellung von arzneimitteln sowie pharmazeutische präparate
ATE318590T1 (de) Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen
ATE282428T1 (de) Pharmazeutische dosierungsform von amorphem nilfenavir mesylat
DE60213592D1 (de) Flüssige pharmazeutische zusammensetzung
DE60235719D1 (de) Frauenhygieneartikel zur verabreichung von arzneimittel
DE60232251D1 (de) Pharmazeutische zusammensetzungen zur behandlung von asthma
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
DE60126321D1 (de) Gelsystem zur ocularen verabreichung von arzneimitteln
EE200300370A (et) Atsüülitud 6,7,8,9-tetrahüdro-5H-bensotsükloheptenüülamiinid, nende valmistamismeetod, kasutamine ja farmatseutiline preparaat
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
ECSP045171A (es) Régimen de dosificación y composición farmacéutica para anticoncepción de emergencia
DE60037816D1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
DE60018081D1 (de) Pharmazeutische zusammensetzungen zur oralen und topischen verabreichung
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
HK1064042A1 (en) Medicines and medicinal kits
EP1476174A4 (de) Pharmazeutische zubereitung mit einem prophylaktischen effekt auf krankheitsrückfälle und pharmokoresistenz im zusammenhang mit lamivudin und methoden zu ihrer verwendung
FR2820311B3 (fr) Distributeur de medicament portatif
DE60218683D1 (de) Pharmazeutische zusammensetzung für die nasale verabreichung von östradiol und norethisteron
DE10291905D2 (de) Pharmazeutische Zusammensetzung
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
DE60214533D1 (de) Pyridoindolonderivate und antikrebsmittel enthaltende pharmazeutische mischungen
DE10107261B4 (de) Pharmazeutische Zusammensetzung
EE200300563A (et) Bensüülaminopürimidiiniühendid, nende kasutamine ja ravim
GB0201607D0 (en) Formulation for the administration of medicinal substances

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee